Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma.

Preoperative elevations in the levels of serum amyloid A (SAA) or C-reactive protein (CRP) have been reported to be prognostic indicators in several malignancies. The aim of this study is to evaluate the serum levels of SAA and CRP in the prognosis of esophageal squamous cell carcinoma (ESCC). In total, 252 patients with ESCC who had undergone surgery with curative-intent were retrospectively recruited. The specificity, sensitivity, and prognostic value of SAA or CRP levels were measured as the area under the receiver operating characteristic (ROC) curve (AUC). The clinical value of SAA and CRP levels as prognostic indicators was evaluated using Cox's proportional hazards model. The 1-, 3-, and 5-year overall survival (OS) rates for the entire cohort of patients with ESCC were 71.0%, 61.0%, and 43.0%, respectively. The correlation between the levels of SAA and CRP was significant (r(2) = 0. 685, P < 0.001). The ROC analysis showed that the levels of CRP were associated with a significantly lower overall accuracy than were the SAA levels (AUC, 0.615 vs. 0.880; P < 0.001). For the complete cohort, the median OS was 52.0 months longer in patients with low preoperative serum levels of SAA (72.0 months) compared with patients who had high SAA levels (20.0 months, P < 0.001). The median OS among patients with low CRP levels was also longer compared with the patients who had high CRP levels (72.0 vs. 51.0 months, respectively; P < 0.001). Subgroup analyses showed that the preoperative elevated levels of SAA could find significant differences in OS for stage I, stage II, and stage III (P < 0.001, P = 0.001, and P < 0.001, respectively), whereas the increased levels of CRP could only find a difference in OS for stage II cancers. After a multivariate analysis, preoperative elevated level of SAA was found to be an independently and significant prognostic factor (P < 0.001). Our study indicates that the preoperative levels of SAA and CRP can act as prognostic factors, and that elevated levels of these proteins are associated with negative effects on the survival of patients with ESCC. SAA showed a higher prognostic value than CRP in both cohort and subgroup analysis.

[1]  Wan-Li Liu,et al.  Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma , 2012, BMC Cancer.

[2]  J. Nikliński,et al.  Comparative Evaluation of Serum C‐Reactive Protein (CRP) Levels in the Different Histological Subtypes of Esophageal Cancer (Squamous Cell Carcinoma and Adenocarcinoma of Esophagus) , 2012, Journal of clinical laboratory analysis.

[3]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[4]  Birgit Grund,et al.  Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves , 2010, Current opinion in HIV and AIDS.

[5]  Eugene H. Blackstone,et al.  7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction , 2010, Annals of Surgical Oncology.

[6]  U. Zingg,et al.  Association of C-Reactive Protein Levels and Long-Term Survival after Neoadjuvant Therapy and Esophagectomy for Esophageal Cancer , 2010, Journal of Gastrointestinal Surgery.

[7]  P. Allavena,et al.  Molecular pathways and targets in cancer-related inflammation , 2010, Annals of medicine.

[8]  Chang-Yu Wang,et al.  Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  G. Marhaug,et al.  Serum amyloid A protein in acute myocardial infarction. , 2009, Acta medica Scandinavica.

[10]  C. Ulrich,et al.  Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors , 2009, Breast Cancer Research and Treatment.

[11]  T. Erlinger,et al.  C‐reactive protein and colorectal cancer risk: A systematic review of prospective studies , 2008, International journal of cancer.

[12]  C. D'Orsi,et al.  Influence of computer-aided detection on performance of screening mammography. , 2007, The New England journal of medicine.

[13]  D. McMillan,et al.  Systemic Inflammatory Response, Prostate-Specific Antigen and Survival in Patients with Metastatic Prostate Cancer , 2006, Urologia Internationalis.

[14]  Kevin R Coombes,et al.  Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. , 2005, International journal of oncology.

[15]  J. Triboulet,et al.  Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. , 2005, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[16]  G. Anderson,et al.  Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. , 2003, Cancer research.

[17]  Y. Maehara,et al.  Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker. , 2003, Cancer letters.

[18]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[19]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[20]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[21]  M. Kitajima,et al.  Surgical treatment of esophageal cancer--the advent of the era of individualization. , 2002, The New England journal of medicine.

[22]  L. Ke.  Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970–90 , 2002, International journal of cancer.

[23]  C. McArdle,et al.  The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer , 2002, British Journal of Cancer.

[24]  K Sugimachi,et al.  Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. , 2001, American journal of surgery.

[25]  H. Ochs,et al.  CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk. , 2001, Blood.

[26]  A. Stewart,et al.  Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. , 2000, Journal of the American College of Surgeons.

[27]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[28]  R. Hershkoviz,et al.  Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. , 1996, Journal of immunology.

[29]  R. Hershkoviz,et al.  Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. , 1994, European journal of biochemistry.

[30]  D. Schultz,et al.  Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. , 1990, Seminars in arthritis and rheumatism.

[31]  C. Maury,et al.  Comparative study of serum amyloid A protein and C-reactive protein in disease. , 1985, Clinical science.

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  Magdalena Kowalewska,et al.  Systemic inflammation as a confounding factor in cancer biomarker discovery and validation , 2010, Nature Reviews Cancer.